- Home
- HOLO vs OVID Comparison
HOLO vs OVID Comparison
Compare HOLO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- OVID
- Stock Information
- Founded
- HOLO 2018
- OVID 2014
- Country
- HOLO China
- OVID United States
- Employees
- HOLO N/A
- OVID N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- OVID Health Care
- Exchange
- HOLO Nasdaq
- OVID Nasdaq
- Market Cap
- HOLO 50.1M
- OVID 47.1M
- IPO Year
- HOLO N/A
- OVID 2017
- Fundamental
- Price
- HOLO $0.79
- OVID $0.31
- Analyst Decision
- HOLO
- OVID Strong Buy
- Analyst Count
- HOLO 0
- OVID 6
- Target Price
- HOLO N/A
- OVID $3.03
- AVG Volume (30 Days)
- HOLO 28.2M
- OVID 406.6K
- Earning Date
- HOLO 08-10-2023
- OVID 03-11-2025
- Dividend Yield
- HOLO N/A
- OVID N/A
- EPS Growth
- HOLO N/A
- OVID N/A
- EPS
- HOLO N/A
- OVID N/A
- Revenue
- HOLO $39,771,750.00
- OVID $566,000.00
- Revenue This Year
- HOLO N/A
- OVID N/A
- Revenue Next Year
- HOLO N/A
- OVID $36.11
- P/E Ratio
- HOLO N/A
- OVID N/A
- Revenue Growth
- HOLO 42.62
- OVID 44.39
- 52 Week Low
- HOLO $0.67
- OVID $0.30
- 52 Week High
- HOLO $92.20
- OVID $3.45
- Technical
- Relative Strength Index (RSI)
- HOLO 40.44
- OVID 22.38
- Support Level
- HOLO $0.73
- OVID $0.42
- Resistance Level
- HOLO $0.92
- OVID $0.48
- Average True Range (ATR)
- HOLO 0.16
- OVID 0.05
- MACD
- HOLO 0.02
- OVID -0.01
- Stochastic Oscillator
- HOLO 21.62
- OVID 3.84
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.